Connect with us


Parkinson’s disease therapy pipeline offers promising new treatment hope



It was in 1817 that Parkinson’s disease was first described as a neurological disorder.

In a detailed medical essay written by the London-based doctor who was to go on and give his name to the progressive disease, James Parkinson, he talked about the ‘shaking palsy’.

More than 200 years on, and whilst scientists have made huge leaps in understanding the neurodegenerative disorder, there is currently no cure. Treatments hinge on relieving symptoms with the limited drugs currently available, and maintaining quality of life.

Those drugs have largely remained unchanged for decades, however, and usually involve taking one called levodopa alongside other medications.

Game-changing therapies could soon be on the horizon, though, as scientists push the boundaries in the hunt for treatments that slow – or ideally reverse – the progress of Parkinson’s disease, which is caused by a loss of cells that produce the neurotransmitter dopamine.

This causes neurons to fire out of control, leading to Parkinson’s hallmark symptoms of tremors in the limbs and head, impaired balance, muscle stiffness, slowness of movement, and possible mental confusion and speech problems.

But according to business consultant and market research firm, DelveInsight, the Parkinson’s disease clinical trial pipeline space is brimming with novel emerging therapies with over 120 active players globally working to develop 140-plus treatments.

Key Parkinson’s disease companies currently working to improve the treatment landscape include Cerevel Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, United Neuroscience Ltd, Luye Pharma Group, Takeda, Xoc Pharmaceuticals, AstraZeneca, MedImmune, and Kissei Pharmaceutical.

In its Parkinson’s Disease Pipeline Insight – 2023 report,  DelveInsight says there are promising pipeline therapies in various stages of development.

These encompass Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, adipose-derived mesenchymal stem cells, ND0612, P2B001, 1ST-103, 1ST-105, and others.

In January this year, Neurocrine Biosciences and Voyager Therapeutics announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. 

The collaboration includes Voyager’s preclinical, intravenously administered GBA1 gene therapy programme for Parkinson’s.

In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programmes directed to rare central nervous system (CNS) targets.

In October 2022, Biogen and Denali Therapeutics announced that dosing had commenced in the global Phase 3 Lighthouse study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson’s disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene.

And, in September 2022, Neuron23, an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing and academic and pharmaceutical research, announced a collaboration.

They are looking to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease.

Other recent advancements cover Neuroderm’s liquid levodopa/carbidopa known as ND0612, which it was announced earlier this year had shown positive phase three trial results, and adipose-derived mesenchymal stem cells.

Stem cell therapy may benefit Parkinson’s disease by replacing and repairing damaged nerve cells within the brain.

Meanwhile Tavapadon, being developed by Cerevel Therapeutics, has shown improvements in movement symptoms.

The cause of Parkinson’s disease is still largely unknown. But it is a progressive disorder caused by nerve cell degeneration in the substantia nigra, a part of the brain that controls movement.

These nerve cells die or become impaired, losing the ability to produce dopamine, an important chemical.

Theories as to the potential causes of the disease involve oxidative damage, environmental toxins, genetic factors, and accelerated aging.

The majority of Parkinson’s patients are given medications to alleviate their symptoms. These work by either stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibiting some of the acetylcholine produced (anticholinergic medications), restoring the balance of chemicals in the brain.

Many celebrities have been diagnosed with Parkinson’s and have been vocal about the condition, helping to raise its profile globally.

They include the Scottish comedian Billy Connolly, the actors Ian Holm, Bob Hoskins, Michael J Fox and Alan Alda, former US President George HW Bush, boxer Muhammad Ali, the singers Neil Diamond and Ozzy Osbourne, TV presenter Jeremy Paxman, and Pope John Paul II.



Air pollution linked to increased hospital admission for heart and lung diseases



Exposure to fine particulate matter (PM2.5) air pollution is linked to an increased risk of hospital admission for major heart and lung diseases, find two large US studies, published by The BMJ.

Together, the results suggest that no safe threshold exists for heart and lung health.

According to the Global Burden of Disease study, exposure to PM2.5 accounts for an estimated 7.6% of total global mortality and 4.2% of global disability adjusted life years (a measure of years lived in good health).

In light of this extensive evidence, the World Health Organization (WHO) updated the air quality guidelines in 2021, recommending that an annual average PM2.5 levels should not exceed 5 μg/m3 and 24 hour average PM2.5 levels should not exceed 15 μg/m3 on more than 3-4 days each year.

In the first study, researchers linked average daily PM2.5 levels to residential zip codes for nearly 60 million US adults (84 per cent white, 55 per cent women) aged 65 and over from 2000 to 2016. They then used Medicare insurance data to track hospital admissions over an average of eight years.

After accounting for a range of economic, health and social factors, average PM2.5 exposure over three years was associated with increased risks of first hospital admissions for seven major types of cardiovascular disease – ischemic heart disease, cerebrovascular disease, heart failure, cardiomyopathy, arrhythmia, valvular heart disease, and thoracic and abdominal aortic aneurysms.

Compared with exposures of 5 μg/m3 or less (the WHO air quality guideline for annual PM2.5), exposures between 9 and 10 μg/m3, which encompassed the US national average of 9.7 μg/m3 during the study period, were associated with a 29% increased risk of hospital admission for cardiovascular disease.

On an absolute scale, the risk of hospital admission for cardiovascular disease increased from 2.59% with exposures of 5 μg/m3 or less to 3.35% at exposures between 9 and 10 μg/m3.

“This means that if we were able to manage to reduce annual PM2.5 below 5 µg/m3, we could avoid 23% in hospital admissions for cardiovascular disease,” say the researchers.*

These cardiovascular effects persisted for at least three years after exposure to PM2.5, and susceptibility varied by age, education, access to healthcare services, and area deprivation level.

The researchers say their findings suggest that no safe threshold exists for the chronic effect of PM2.5 on overall cardiovascular health, and that substantial benefits could be attained through adherence to the WHO air quality guideline.

“On February 7, 2024, the US Environmental Protection Agency (EPA) updated the national air quality standard for annual PM2.5 level, setting a stricter limit at no more than 9 µg/m3. This is the first update since 2012. However, it is still considerably higher than the 5 µg/m3 set by WHO. Obviously, the newly published national standard was not sufficient for the protection of public health,” they add.*

In the second study, researchers used county-level daily PM2.5 concentrations and medical claims data to track hospital admissions and emergency department visits for natural causes, cardiovascular disease, and respiratory disease for 50 million US adults aged 18 and over from 2010 to 2016.

During the study period, more than 10 million hospital admissions and 24 million emergency department visits were recorded.

They found that short term exposure to PM2.5, even at concentrations below the new WHO air quality guideline limit, was statistically significantly associated with higher rates of hospital admissions for natural causes, cardiovascular disease and respiratory disease, as well as emergency department visits for respiratory disease.

For example, on days when daily PM2.5 levels were below the new WHO air quality guideline limit of 15 μg/m3, an increase of 10 μg/m3 in PM2.5 was associated with 1.87 extra hospital admissions per million adults aged 18 and over per day.

The researchers say their findings constitute an important contribution to the debate about the revision of air quality limits, guidelines, and standards.

Both research teams acknowledge several limitations such as possible misclassification of exposure and point out that other unmeasured factors may have affected their results. What’s more, the findings may not apply to individuals without medical insurance, children and adolescents, and those living outside the US.

However, taken together, these new results provide valuable reference for future national air pollution standards.

Continue Reading


Home health care linked to increased hospice use at end-of-life – study



Patients who had previously received home health care had a higher likelihood of accessing hospice care at the end of their life, according to a new study.

Researchers, whose findings are published in the Journal of Palliative Medicine, examined the home health care and hospice care experiences of more than two million people.

Using Medicare data, researchers found when individuals received home health care before the last year of their life, they had higher odds of using hospice care than those who had never received home health care.

Researchers said this association underscores the potential benefits of receiving end-of-life care in the comfort of one’s home.

As the aged population increases, the findings also show the need for more resources in the health care sector and staff training in end-of-life care.

Home health care services including skilled nursing, therapy, social work and aide services are used to maintain functioning or slow decline in health. Hospice care provides similar services but is intended for those with life expectancies of six months or less and is focused on pain relief, minimising hospital visits and providing comfort and support. Both services provide patients the opportunity to receive more personalised care in their home.

Researchers say home-based care also encourages greater involvement of family caregivers in the caregiving process.

Olga Jarrín, senior author of the study, the Hunterdon Professor of Nursing Research at the Rutgers School of Nursing and director of the Community Health and Aging Outcomes Laboratory within the Rutgers Institute for Health, Health Care Policy and Aging Research, commented: “In addition to benefits for the patient, hospice care also provides resources and support to help family caregivers cope with the physical, emotional and practical challenges of caring for a loved one at the end of life.”

Hyosin (Dawn) Kim, research assistant professor at Oregon State University and first author of the study, added: “By providing personalised care, reducing hospitalisations, fostering family involvement and support, and improving symptom management, home-based care can enhance the quality of end-of-life experiences for patients with terminal illnesses and their families.”


Continue Reading


Sleep programme shows promise in those with memory problems – study



A new study has shown promising results in improving sleep and quality of life in individuals living with memory problems.

A group of researchers from Penn Nursing, Penn Medicine, Rutgers School of Nursing, and Drexel University’s College of Nursing and Health Professions, have delved into the efficacy of a non-pharmacological approach in a trial known as the Healthy Patterns Sleep Program.

The study involved 209 pairings of community-residing individuals with memory problems and their care partners. Participants were assigned to either the Healthy Patterns Sleep Program, which consisted of one-hour home activity sessions administered over four weeks, or a control group that received sleep hygiene training, plus education on home safety and health promotion.

The Healthy Patterns Sleep Program trained care partners in timed daily activities such as reminiscence in the morning, exercise in the afternoon and sensory activities in the evening that can decrease daytime sleepiness and improve nighttime sleep quality.

Nancy Hodgson, PhD, RN, FAAN, the Claire M. Fagin Leadership Professor in Nursing and Chair of Department of Biobehavioral Health Sciences, who led the study, said: “The results from this study provide fundamental new knowledge regarding the effects of timing activity participation and can lead to structured, replicable treatment protocols to address sleep disturbances. Overall, the Healthy Patterns program resulted in improved QOL compared to an attention-control group.”

The findings also indicate that, compared to a control group, the four-week Healthy Patterns program improved sleep quality among persons living with memory issues who had depressive symptoms or poor sleep quality.  The study indicates the Healthy Patterns Intervention might need a longer dose to induce improvements in other sleep-wake activity metrics.

The study’s significance lies in its confirmation of the effectiveness of behavioural interventions in not only improving quality of life and addressing sleep quality issues in this population, but also potentially reducing care partner burden and overall care costs for persons living at home with memory problems.

Continue Reading